Skip to main content
PMC home page
Journal of Cellular and Molecular Medicine logoLink to Journal of Cellular and Molecular Medicine
. 2007 May 1;7(4):461–471. doi: 10.1111/j.1582-4934.2003.tb00249.x

Sertoli‐Leydig cell tumor ‐ a rare androgen secreting ovarian tumor in postmenopausal women: case report and review of literature

Ancuta Gheorghisan‐Galateanu 1,✉, Simona Fica 2, Dana Cristina Terzea 3, Andra Caragheorgheopol 4, V Horhoianu 5
PMCID: PMC6740084  PMID: 14754515

Abstract

Sertoli‐Leydig cell tumors (SLCT) constitute only 1‐0.5% of all primary ovarian neoplasms. We report a SLCT in a postmenopausal woman aged 69 years. The physical examination revealed severe hirsutism. Basal hormonal evaluation showed high plasma testosterone and estradiol values, with suppressed plasma gonadotropins. Computer tomograph scan revealed a right ovarian tumor mass of 4,3/3 cm, confirming an androgen secreting ovarian tumor. The histopathological and immunocytochemical examination established the diagnosis of well differentiated Sertoli‐Leydig cell tumor. The tumor was positive for cytokeratin KL 1 and S‐100 protein and, in isolated tumor cells, positive for alpha‐fetoprotein. Postsurgical evolution was favorable; controls after 6 months and 3,5 years showed marked reduction of hirsutism, normal plasma testosterone values and gonadotropins in normal postmenopausal range. We discuss the complex aspects of etiology and pathogenesis, the clinical and hormonal settings, the role of immunocytochemical markers in diagnosis, as well as the therapy and the prognostic features of this ovarian tumor.

Keywords: androgen secreting ovarian tumor, Sertoli‐Leydig cell tumor, postmenpause, diagnosis, pathogenesis

References

  • 1. Montella L., Virilizing ovarian tumors: arrhenoblastoma, Rass. Int. Clin. Ter., 52: 732–738, 1972. [PubMed] [Google Scholar]
  • 2. Maschler I., Weidenfeld J., Fleischer B., Ehrenfeld E.N., Finkelstein M., Steroidogenesis in a virilizing ovarian tumor, Clin. Endocrinol., 4: 427–436, 1975. [DOI] [PubMed] [Google Scholar]
  • 3. Fleckenstein G., Sattler B., Hinney B., Wuttke W., Osmers R., Emons G., Androblastoma of the ovary: clinical, diagnostic and histopthologic features, Onkologie, 24: 286–291, 2001. [DOI] [PubMed] [Google Scholar]
  • 4. Young R., Clement P.B., Scully R.E., The ovary In: Diagnostic Surgical Pathology, Raven Press, New York , 1989, pp. 1687–1690. [Google Scholar]
  • 5. Tanaka Y.O., Ide Y., Nishida M., Nishide K., Tsunoda H., Kajitani M., Itai Y., Ovarian tumor with functioning stroma, Comput. Med. Imaging Graph., 26: 193–197, 2002. [DOI] [PubMed] [Google Scholar]
  • 6. Britt K.L., Findlay J.K., Regulation of the phenotype of ovarian somatic cells by estrogen, Mol. Cel. Endocrinol., 202: 11–17, 2003. [DOI] [PubMed] [Google Scholar]
  • 7. Couse J.F., Curtis Hewitt S., Bunch D.O., Sar M., Walker V.R., Davis B.J., Korach K.S., Postnatal sex reversal of the ovaries in mice lacking estrogen receptors a and b, Science, 286: 2328–2331, 1999. [DOI] [PubMed] [Google Scholar]
  • 8. Mandurino S., Mazzei C., A case of ovarian arrhenoblastoma, Arch. Sci. Med., 139: 139–142, 1982. [PubMed] [Google Scholar]
  • 9. Takekawa Y., Kimura M., Sakakibara R., Yoshii R., Ato M., Nemoto N., Sakurai I., Immunohistochemical study of Sertoli‐stromal cell tumor; comparison between the tumor arising from the gonad of a testicular feminization syndrome bearing patient and from ovaries of non‐bearing patients, Rinsho. Byori., 47: 1070–1074, 1999. [PubMed] [Google Scholar]
  • 10. O'Hern T.M., Neubecker R.D., Arrhenoblastoma of the ovary, Obste. Gynecol., 19: 758–770, 1962. [PubMed] [Google Scholar]
  • 11. Ketola I., Pentikainen V., Vaskivuo T., Ilvesmaki V, Herva R., Dunkel L., Tapanainen J.S., Toppari J., Heikinheimo M., Expression of transcription factor GATA‐4 during human testicular development and diseas, J. Clin. Endocrinol. Metab., 85: 3925–3931, 2000. [DOI] [PubMed] [Google Scholar]
  • 12. Hitosugi M., Matsuoka Y., Irimajiri S., Fukuda J., Sertoli‐Leydig cell tumour complicated by X chromosomal mosaicism, Clin. Endocrinol., 47: 619–622, 1997. [DOI] [PubMed] [Google Scholar]
  • 13. De Giorgi U., Turci D., Crisanti E., Cantu M.G., Cappelini A., Marangolo M., Ovarian Sertoli‐Leydig cell tumor, endometrioid‐like yolk sac tumor, and Y‐chromosomal material, Oncology, 64: 370–3, 2003. [DOI] [PubMed] [Google Scholar]
  • 14. Stegner H‐E., Lisboa B.P., Steroid metabolism in an androblastoma (Sertoli‐Leydig cell tumor). A histopathological and biochemical study, Int. J. Gynecol. Pathol., 2: 410–425, 1984. [DOI] [PubMed] [Google Scholar]
  • 15. Fleetwood J.A., Watson M.J., Wastell H.J., Weddell A., Hormone studies in a case of virilisation due to ovarian tumor, Ann. Clin. Biochem., 22: 498–501, 1985. [DOI] [PubMed] [Google Scholar]
  • 16. Tita P., Spina A., Briguglia G., Magro A., Gallo D., Finocchiaro C., Padova G., Pezzino V., Clinical features and hormonal characteristics in a case of ovarian arrhenoblastoma, J. Endocrinol. Invest., 19: 484–487, 1996. [DOI] [PubMed] [Google Scholar]
  • 17. Viollier E.H., Young D.S., What is your diagnosis?, Arrhenoblastoma Schweiz. Rundsch. Med. Prax., 71: 205–206, 1982. [PubMed] [Google Scholar]
  • 18. Graham C.E., McClure H.M., Sertoli‐Leydig cell tumor in a chimpanzee, Lab. Anim. Sci., 26: 948–950, 1976. [PubMed] [Google Scholar]
  • 19. Kommoss F., Oliva E., Bhan A.K., Young R.H., Scully R.E., Inhibin expression in ovarian tumors and tumor‐like lesions: an immunohistochemical study, Mod. Pathol., 11: 656–664, 1998. [PubMed] [Google Scholar]
  • 20. Singh Z.N., Singh M.K., Chopra P. Sertoli Leydig cell tumor with malignant heterologous elements and raised alpha‐fetoprotein: a case report, J. Obstet. Gynaecol. Res., 22: 595–598, 1996. [DOI] [PubMed] [Google Scholar]
  • 21. Aboud E., A review of granulosa cell tumours and thecomas of the ovary, Arch. Gynecol. Obstet., 259: 161–165, 1997. [DOI] [PubMed] [Google Scholar]
  • 22. Mooney E.E., Man Y.G., Bratthauer G.L., Tavassoli F.A., Evidence that Leydig cells in Sertoli‐Leydig cell tumors have a reactive rather than a neoplastic profile, Cancer, 86: 2312–2319, 1999. [DOI] [PubMed] [Google Scholar]
  • 23. Young R.H., Sertoli‐Leydig cell tumors of the ovary: Review with emphasis on historical aspects and unusual variants, Int. J. Gynecol. Pathol., 12: 141–147, 1993. [DOI] [PubMed] [Google Scholar]
  • 24. Kurman R.J., Andrade D., Goebelsmann U., Taylor C.R., An immunohistological study of steroid localization in Sertoli‐Leydig tumors of the ovary and testis, Cancer, 42: 1772–1783, 1978. [DOI] [PubMed] [Google Scholar]
  • 25. Haider S.G., Pickartz H., Freundl G., Passia D., Demonstration of hydroxisteroid dehydrogenases and testosterone in the Sertoli‐Leydig cell tumor (androblastoma) tissue of the human ovary: an enzyme histochemical and immunohistochemical study, Acta Anat., 121: 170–173, 1985. [DOI] [PubMed] [Google Scholar]
  • 26. Costa M.J., Morris R.J., Wilson R., Judd R. Utility of immunohistochemistry in distinguishing ovarian Sertoli stromal cell tumors from carcinosarcomas, Hum. Pathol., 23: 787–797, 1992. [DOI] [PubMed] [Google Scholar]
  • 27. Costa M.J., Ames P.F., Walls J., Roth L.M. Inhibin immunohistochemistry applied to ovarian neoplasms: a novel, effective, diagnostic tool, Hum. Pathol., 28: 1247–1254, 1997. [DOI] [PubMed] [Google Scholar]
  • 28. Riopel M.A., Perlman E.J., Seidman J.D., Kurman R.J., Sherman M.E., Inhibin and epithelial membrane antigen immunohistochemistry assist in the diagnosis of sex cordstromal tumors and provide clus to the histogenesis of hypercalcemic small cell carcinomas, Int. J. Gynecol. Pathol., 17: 46–53, 1998. [DOI] [PubMed] [Google Scholar]
  • 29. Kommoss F., Oliva E., Bhan A.K., Young R.H., Scully R.E., Inhibin expression in ovarian tumors and tumor‐like lesions: an immunohistochemical study, Mod. Pathol., 11: 656–664, 1998. [PubMed] [Google Scholar]
  • 30. Mooney E.E., Nogales F.F., Tavassoli F.A. Hepatocytic differentiation in retiform Sertoli‐Leydig cell tumors: distinguishing a heterologous element from Leydig cells, Hum. Pathol., 30: 611–617, 1999. [DOI] [PubMed] [Google Scholar]
  • 31. Klonisch T., Hombach‐Klonisch S., Buchmann J, Fischer B., Bergmann M., Steger K. Relaxin‐like factor expression in a human ovarian Sertoli‐Leydig cell tumor,. Fertil. Steril.,. 72: 546–568, 1999. [DOI] [PubMed] [Google Scholar]
  • 32. Inoue Y., Kamura T., Okuma A., Shigematsu T., Amada S., Ogata R., Koga M., Nozaki M., Nakano H., Efficacy of selective venous sampling to localize a small ovarian androgen‐producing tumor, J. Obstet. Gynaecol. Res., 25: 231–236, 1999. [DOI] [PubMed] [Google Scholar]
  • 33. Lantzsch T., Stoerer S., Lawrenz K., Buchmann J., Strauss H.G., Koelbl H., Sertoli‐Leydig cell tumor, Arch. Gynecol. Obstet., 264: 206–208, 2001. [DOI] [PubMed] [Google Scholar]
  • 34. Yang S.W., Cho M.Y., Jung S.H., Lee K.G., Cha D.S., Kim K.R., Mucinous cystadenoma coexisting with stromal tumor with minor sex‐cord elements of the ovary: a case report, J. Korean. Med. Sci., 16: 237–240, 2001. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 35. Golbang P., Khan A., Scurry J., Maclsaac I., Planner R., Cervical sarcoma botryoides and ovarian Sertoli‐Leydig cell tumor, Gynecol. Oncol., 67: 102–106, 1997. [DOI] [PubMed] [Google Scholar]
  • 36. Seo E.J., Kwon H.J., Shim S.I. Ovarian serous cystadenoma associated with Sertoli‐Leydig cell tumor‐a case report, J. Korean. Med. Sci., 11: 84–87, 1996. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 37. Spremovic‐Radjenovic S, Radosavljevic A, Petkovic S, Matijasevic S., Cvetkovic M., Lazovic G., Popovic V., The polycystic ovary syndrome associated with ovarian tumor, Srp. Arh. Celok. Lek., 125: 375–377, 1997. [PubMed] [Google Scholar]
  • 38. Latthe P., Shafi M.I., Rollason T.P., Recurrence of Sertoli‐Leydig cell tumor in controlateral ovary. Case report and review of literature, Eur. J. Gynaecol. Oncol., 21: 62–63, 2000. [PubMed] [Google Scholar]
  • 39. Campisi P., Cheski P., Metastatic Sertoli‐Leydig cell ovarian cancer manifested as a frontal sinus mass, J. Otolaryngol., 27: 361–362, 1998. [PubMed] [Google Scholar]
  • 40. Dowdy S.C., O'Kane D.J., Keeney G.L., Boyd J, Podratz K.C., Telomerase activity in sex cord‐stromal tumors of the ovary, Gynecol. Oncol., 82: 257–260, 2001. [DOI] [PubMed] [Google Scholar]
  • 41. Zheng P.S., Iwasaka T., Yamasaki F., Ouchida M., Yokoyama M., Nakao Y., Fukuda K., Matsuyama T., Sugimori H., Telomerase activity in gynecologic tumors, Gynecol. Oncol., 64: 171–175, 1997. [DOI] [PubMed] [Google Scholar]
  • 42. Manegold E., Tietze L., Günther K., Fleischer A., Amo‐Takyi B.K., Schröder W., Handt S., Trisomy 8 as sole karyotypic aberration in an ovarian metastasizing Sertoli‐Leydig cell tumor, Hum. Pathol., 32: 559–562, 2001. [DOI] [PubMed] [Google Scholar]
  • 43. Chao H.T., Wang P.H., Lin H.D., Gonadotropin‐releasing hormone‐agonist as a neoadjuvant therapy for Sertoli‐Leydig cell tumors of the ovary, Int. J. Gynaecol. Obstet., 66: 189–190, 1999. [DOI] [PubMed] [Google Scholar]
  • 44. Gershenson D.M., Morris M., Burke T.W., Levenback C., Matthews C.M., Wharton J.T., Treatment of poorprognosis sex cord‐stromal tumors of the ovary with the combination of bleomycin, etoposide, and cisplatin, Obstet. Gynecol., 87: 527–531, 1996. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Cellular and Molecular Medicine are provided here courtesy of Blackwell Publishing

RESOURCES